China · Delayed Price · Currency is CNY GemPharmatech Statistics
Total Valuation
GemPharmatech has a market cap or net worth of CNY 14.05 billion. The enterprise value is 13.24 billion.
| Market Cap | 14.05B |
| Enterprise Value | 13.24B |
Important Dates
The last earnings date was Thursday, August 20, 2026.
| Earnings Date | Aug 20, 2026 |
| Ex-Dividend Date | Jun 9, 2026 |
Share Statistics
GemPharmatech has 408.97 million shares outstanding. The number of shares has decreased by -2.46% in one year.
| Current Share Class | 408.97M |
| Shares Outstanding | 408.97M |
| Shares Change (YoY) | -2.46% |
| Shares Change (QoQ) | +9.12% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | 12.63% |
| Float | 165.77M |
Valuation Ratios
The trailing PE ratio is 76.06 and the forward PE ratio is 70.10.
| PE Ratio | 76.06 |
| Forward PE | 70.10 |
| PS Ratio | 16.00 |
| PB Ratio | 6.20 |
| P/TBV Ratio | 6.39 |
| P/FCF Ratio | 60.97 |
| P/OCF Ratio | 46.86 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 46.10, with an EV/FCF ratio of 57.48.
| EV / Earnings | 72.55 |
| EV / Sales | 15.08 |
| EV / EBITDA | 46.10 |
| EV / EBIT | 65.78 |
| EV / FCF | 57.48 |
Financial Position
The company has a current ratio of 3.63, with a Debt / Equity ratio of 0.10.
| Current Ratio | 3.63 |
| Quick Ratio | 3.12 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | 0.81 |
| Debt / FCF | 1.01 |
| Interest Coverage | 62.51 |
Financial Efficiency
Return on equity (ROE) is 8.23% and return on invested capital (ROIC) is 11.91%.
| Return on Equity (ROE) | 8.23% |
| Return on Assets (ROA) | 4.46% |
| Return on Invested Capital (ROIC) | 11.91% |
| Return on Capital Employed (ROCE) | 8.50% |
| Weighted Average Cost of Capital (WACC) | 8.83% |
| Revenue Per Employee | 552,283 |
| Profits Per Employee | 114,809 |
| Employee Count | 1,590 |
| Asset Turnover | 0.31 |
| Inventory Turnover | 3.99 |
Taxes
In the past 12 months, GemPharmatech has paid 29.20 million in taxes.
| Income Tax | 29.20M |
| Effective Tax Rate | 13.79% |
Stock Price Statistics
The stock price has increased by +91.15% in the last 52 weeks. The beta is 0.86, so GemPharmatech's price volatility has been lower than the market average.
| Beta (5Y) | 0.86 |
| 52-Week Price Change | +91.15% |
| 50-Day Moving Average | 26.83 |
| 200-Day Moving Average | 19.77 |
| Relative Strength Index (RSI) | 55.39 |
| Average Volume (20 Days) | 18,491,892 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, GemPharmatech had revenue of CNY 878.13 million and earned 182.55 million in profits. Earnings per share was 0.45.
| Revenue | 878.13M |
| Gross Profit | 562.24M |
| Operating Income | 201.35M |
| Pretax Income | 211.75M |
| Net Income | 182.55M |
| EBITDA | 279.65M |
| EBIT | 201.35M |
| Earnings Per Share (EPS) | 0.45 |
Balance Sheet
The company has 1.04 billion in cash and 233.60 million in debt, with a net cash position of 804.31 million or 1.97 per share.
| Cash & Cash Equivalents | 1.04B |
| Total Debt | 233.60M |
| Net Cash | 804.31M |
| Net Cash Per Share | 1.97 |
| Equity (Book Value) | 2.27B |
| Book Value Per Share | 5.29 |
| Working Capital | 1.23B |
Cash Flow
In the last 12 months, operating cash flow was 299.80 million and capital expenditures -69.40 million, giving a free cash flow of 230.40 million.
| Operating Cash Flow | 299.80M |
| Capital Expenditures | -69.40M |
| Depreciation & Amortization | 78.31M |
| Net Borrowing | -110.26M |
| Free Cash Flow | 230.40M |
| FCF Per Share | 0.56 |
Margins
Gross margin is 64.03%, with operating and profit margins of 22.93% and 20.79%.
| Gross Margin | 64.03% |
| Operating Margin | 22.93% |
| Pretax Margin | 24.11% |
| Profit Margin | 20.79% |
| EBITDA Margin | 31.85% |
| EBIT Margin | 22.93% |
| FCF Margin | 26.24% |
Dividends & Yields
This stock pays an annual dividend of 0.22, which amounts to a dividend yield of 0.55%.
| Dividend Per Share | 0.22 |
| Dividend Yield | 0.55% |
| Dividend Growth (YoY) | 57.14% |
| Years of Dividend Growth | n/a |
| Payout Ratio | 75.30% |
| Buyback Yield | 2.46% |
| Shareholder Yield | 3.01% |
| Earnings Yield | 1.30% |
| FCF Yield | 1.64% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 7 |